Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma

Area of Science:

• Oncology
• Immunology
• Cancer Cell Biology

Background:

• Immunotherapies targeting immune checkpoints are approved for many cancers, including metastatic melanoma.
• A significant portion of melanoma patients do not respond to or develop resistance against these therapies.
• Non-genetic, cancer cell-intrinsic alterations are increasingly recognized as key drivers of therapeutic resistance and immune evasion.

Purpose of the Study:

• To review recent findings on the role of melanoma cell phenotypic reprogramming in immune evasion and immunotherapy resistance.
• To detail the mechanisms by which dedifferentiated melanoma cells resist T cell-mediated lysis and immune surveillance.
• To highlight how understanding tumor cell plasticity can inform new therapeutic strategies for metastatic melanoma.

Main Methods:

• Literature review of recent research on melanoma cell plasticity.
• Analysis of mechanisms driving immune evasion in dedifferentiated melanoma cells.
• Discussion of phenotypic reprogramming's impact on the tumor immune microenvironment.

Main Results:

• Melanoma cell plasticity, involving EMT-like dedifferentiation, contributes to immune evasion.
• Dedifferentiated melanoma cells acquire features that allow them to escape T cell recognition and lysis.
• These cellular changes can also lead to T cell exclusion and remodeling of the tumor immune microenvironment.

Conclusions:

• Phenotypic reprogramming is a critical mechanism of resistance to immunotherapy in melanoma.
• Targeting tumor cell plasticity alongside immunotherapy may overcome treatment resistance.
• Further research into melanoma cell plasticity is essential for developing improved combination therapies for metastatic melanoma.